Dushyant Verma, MD
Hematology & Oncology · Springfield, MONPI 1164477014
Payments from drug & device makers
Across 50 payments — averaging $31.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$214
- Intuitive Surgical$150
- Abbott$150
- E.r. Squibb & Sons, L.L.C.$115
- Bristol Myers Squibb$110
- AVEO Pharmaceuticals, Inc.$104
- plus $728 from 21 others
What the payments were for
- Food & beverage$1,28782%
- Education$28418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $214 |
| Intuitive Surgical | 1 | $150 |
| Abbott | 1 | $150 |
| E.r. Squibb & Sons, L.L.C. | 7 | $115 |
| Bristol Myers Squibb | 6 | $110 |
| AVEO Pharmaceuticals, Inc. | 2 | $104 |
| Astellas Pharma US Inc | 1 | $95 |
| Incyte Corporation | 1 | $84 |
| Merck | 4 | $82 |
| Novartis | 3 | $60 |
| AbbVie | 2 | $49 |
| Medtronic | 1 | $39 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $31 |
| Foundation Medicine, Inc. | 1 | $27 |
| AstraZeneca | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Exelixis Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Gilead | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| GSK | 1 | $16 |
| Pfizer | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$150
- AMPLATZER AMULET$150
- RYBREVANT$122
- CARVYKTI$122
How this compares
$1,571 in reported general payments places this provider in the 40th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 72 | $1,145,589 |
| XtandiEnzalutamide | 26 | $372,117 |
| SprycelDasatinib | 20 | $338,025 |
| RevlimidLenalidomide | 19 | $335,424 |
| InlytaAxitinib | 13 | $215,429 |
| TagrissoOsimertinib Mesylate | 12 | $206,969 |
| ErleadaApalutamide | 14 | $192,200 |
| Somatuline DepotLanreotide Acetate | 11 | $103,496 |
| VenclextaVenetoclax | 11 | $68,988 |
| Abiraterone Acetate | 22 | $51,888 |
| TrazimeraTrastuzumab-Qyyp | 15 | $48,211 |
| EliquisApixaban | 35 | $20,090 |
| XareltoRivaroxaban | 12 | $10,275 |
| Exemestane | 26 | $6,402 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 124 | $2,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $31 | $1,145,58972 claims |
| Astellas Pharma US IncXtandi | $95 | $372,11726 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $115 | $338,02520 claims |
| Bristol Myers SquibbRevlimid | $110 | $335,42419 claims |
| PfizerInlyta, Trazimera, Eliquis | $15 | $283,73063 claims |
| AstraZenecaTagrisso | $26 | $206,96912 claims |
| Johnson & JohnsonErleada, Xarelto | $214 | $202,47526 claims |
| AbbVieVenclexta | $49 | $68,98811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Springfield
- Jessica SniderSpringfield$329K
- Mohan TummalaSpringfield$322K
- Robert EllisSpringfield$129K
- Rajesh NairSpringfield$118K
- Raymond LobinsSpringfield$47K
- Stephanie GraffKansas City$6.2M
- Suman KambhampatiKansas City$4.9M
- Geoffrey UySaint Louis$4.1M
- Jaswinder SinghKansas City$3.9M
- Mark FeslerSaint Louis$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.